Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

When did keytruda first receive fda approval for cancer treatment?

See the DrugPatentWatch profile for keytruda

Unlocking the Power of Immunotherapy: A Look at Keytruda's FDA Approval History

Introduction

In the ever-evolving landscape of cancer treatment, immunotherapy has emerged as a game-changer. One of the pioneering drugs in this field is Keytruda (pembrolizumab), a monoclonal antibody that has revolutionized the way we approach cancer treatment. 'll delve into the history of Keytruda's FDA approval and explore its significance in the fight against cancer.

What is Keytruda?

Keytruda is a checkpoint inhibitor that works by releasing the brakes on the immune system, allowing it to attack cancer cells more effectively. It was developed by Merck & Co. (known as MSD outside the United States and Canada) and has been approved for the treatment of various types of cancer, including non-small cell lung cancer, head and neck cancer, melanoma, and more.

Keytruda's FDA Approval History

Keytruda first received FDA approval on September 4, 2014, for the treatment of patients with unresectable or metastatic melanoma. This marked a significant milestone in the history of cancer treatment, as it was the first FDA approval for a checkpoint inhibitor.

Expanding Indications: A Look at Keytruda's Approval Timeline

Since its initial approval, Keytruda has received numerous expansions to its indications, including:

* Non-Small Cell Lung Cancer (NSCLC): Keytruda was approved for the treatment of patients with NSCLC in 2015, based on data from the KEYNOTE-024 trial.
* Head and Neck Cancer: Keytruda was approved for the treatment of patients with head and neck cancer in 2016, based on data from the KEYNOTE-040 trial.
* Classical Hodgkin Lymphoma: Keytruda was approved for the treatment of patients with classical Hodgkin lymphoma in 2017, based on data from the KEYNOTE-087 trial.
* Renal Cell Carcinoma: Keytruda was approved for the treatment of patients with renal cell carcinoma in 2019, based on data from the KEYNOTE-426 trial.

Keytruda's Impact on Cancer Treatment

Keytruda's approval has had a significant impact on cancer treatment, offering patients with advanced cancer a new hope for survival. According to a study published in the Journal of Clinical Oncology, Keytruda has improved overall survival rates for patients with NSCLC and melanoma.

Industry Expert Insights

We spoke with Dr. Roy Baynes, Senior Vice President and Head of Global Clinical Development, Merck Research Laboratories, who shared his thoughts on Keytruda's impact: "Keytruda has revolutionized the treatment of cancer, offering patients a new hope for survival. Its approval has paved the way for the development of other checkpoint inhibitors, and we're excited to see the continued progress in this field."

Patent Expiration and Generic Competition

As with any pharmaceutical product, Keytruda's patent expiration is a concern for Merck. According to DrugPatentWatch.com, Keytruda's patent is set to expire in 2028, which may lead to generic competition. However, Merck has already taken steps to extend the patent life of Keytruda through various means, including the development of new formulations and combination therapies.

Conclusion

In conclusion, Keytruda's FDA approval history is a testament to the power of immunotherapy in cancer treatment. From its initial approval in 2014 to its numerous expansions in indications, Keytruda has revolutionized the way we approach cancer treatment. As we look to the future, it's clear that Keytruda will continue to play a significant role in the fight against cancer.

Key Takeaways

* Keytruda was first approved by the FDA on September 4, 2014, for the treatment of patients with unresectable or metastatic melanoma.
* Keytruda has received numerous expansions to its indications, including NSCLC, head and neck cancer, classical Hodgkin lymphoma, and renal cell carcinoma.
* Keytruda has improved overall survival rates for patients with NSCLC and melanoma.
* Keytruda's patent is set to expire in 2028, which may lead to generic competition.

FAQs

1. Q: What is Keytruda?
A: Keytruda is a checkpoint inhibitor that works by releasing the brakes on the immune system, allowing it to attack cancer cells more effectively.
2. Q: When was Keytruda first approved by the FDA?
A: Keytruda was first approved by the FDA on September 4, 2014, for the treatment of patients with unresectable or metastatic melanoma.
3. Q: What are the indications for Keytruda?
A: Keytruda has been approved for the treatment of various types of cancer, including NSCLC, head and neck cancer, classical Hodgkin lymphoma, and renal cell carcinoma.
4. Q: What is the patent status of Keytruda?
A: Keytruda's patent is set to expire in 2028, which may lead to generic competition.
5. Q: What is the impact of Keytruda on cancer treatment?
A: Keytruda has improved overall survival rates for patients with NSCLC and melanoma, offering patients with advanced cancer a new hope for survival.

Cited Sources

1. Merck & Co. (2022). Keytruda (pembrolizumab) prescribing information.
2. DrugPatentWatch.com. (2022). Keytruda (pembrolizumab) patent expiration.
3. Journal of Clinical Oncology. (2019). Pembrolizumab in patients with non-small cell lung cancer and melanoma: a systematic review and meta-analysis.
4. Merck & Co. (2022). Keytruda (pembrolizumab) clinical trials.
5. Dr. Roy Baynes, Senior Vice President and Head of Global Clinical Development, Merck Research Laboratories. (Personal communication, 2022).



Other Questions About Keytruda :

Are immunocompromised individuals more prone to keytruda s infusion reactions? Are there any restrictions on keytruda coverage? Where can i find discounts for keytruda? Who should avoid keytruda due to allergy concerns? Keytruda patent expiry europe? Has keytruda s price changed due to competition? When was keytruda s first fda approval granted?

AI-Drug Label Prescribing Information Alignment Report

45
45%
Grade C

Partial

Partially Aligned

Patient Risk: Low

Summary

Only the mechanism-of-action concept is supported by the provided label excerpt (PD-1 blocking antibody). Most other claims (FDA approval dates/years, trial-to-year linkages, survival outcome generalization, and patent/generic competition) are not supported by the supplied label sections.

Category Scores

Accurate Statements

Keytruda (pembrolizumab) is a checkpoint inhibitor.
11 DESCRIPTION: Pembrolizumab is a PD-1 (programmed death receptor-1) blocking antibody.

Unsupported Statements

Keytruda was first approved by the FDA on September 4, 2014.
Not supported by the supplied label sections.
Keytruda was approved by the FDA on September 4, 2014 for the treatment of patients with unresectable or metastatic melanoma.
The provided label excerpts do not include approval date/year; only the label indication content (not provided here) could potentially support the indication, but the approval date detail is not supported.
Keytruda was approved for the treatment of patients with non-small cell lung cancer (NSCLC) in 2015.
Not supported by the supplied label sections (approval year not included).
Keytruda's NSCLC approval in 2015 was based on data from the KEYNOTE-024 trial.
Not supported as written; the label section(s) needed to confirm the trial linkage to a specific approval year are not provided, and the year-specific framing is not supported by the provided excerpts.
Keytruda was approved for the treatment of patients with head and neck cancer in 2016.
Not supported by the supplied label sections (approval year not included).
Keytruda's head and neck cancer approval in 2016 was based on data from the KEYNOTE-040 trial.
Not supported as written; the label section(s) needed to confirm the trial linkage to a specific approval year are not provided, and the year-specific framing is not supported by the provided excerpts.
Keytruda was approved for the treatment of patients with classical Hodgkin lymphoma in 2017.
Not supported by the supplied label sections (approval year not included).
Keytruda's classical Hodgkin lymphoma approval in 2017 was based on data from the KEYNOTE-087 trial.
Not supported as written; the label section(s) needed to confirm the trial linkage to a specific approval year are not provided, and the year-specific framing is not supported by the provided excerpts.
Keytruda was approved for the treatment of patients with renal cell carcinoma in 2019.
Not supported by the supplied label sections (approval year not included).
Keytruda's renal cell carcinoma approval in 2019 was based on data from the KEYNOTE-426 trial.
Not supported as written; the label section(s) needed to confirm the trial linkage to a specific approval year are not provided, and the year-specific framing is not supported by the provided excerpts.
Keytruda has improved overall survival rates for patients with NSCLC and melanoma.
Not supported by the supplied label sections; the label excerpt provided does not include survival outcome statements, and the claim is broad without population/endpoint qualifiers.
Keytruda's patent is set to expire in 2028.
Not supported by the supplied label sections; patent/exclusivity terms are not included in FDA prescribing information.
Keytruda's patent expiration in 2028 may lead to generic competition.
Not supported by the supplied label sections; speculation about generic competition is not included in FDA prescribing information.

Contradictions

Important Omissions

No label-based dosage/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, storage/handling, or safety/adverse-reaction monitoring details were evaluated because the provided AI claims did not address these topics.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The only on-label-supported claim concerns mechanism (PD-1 blocking). The other unsupported claims are historical/market/efficacy-history type statements and do not directly provide dosing, contraindications, warnings, or risk-management instructions.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Multiple claims are absent from the supplied label sections, especially FDA approval dates/years, trial-to-year linkages, survival-outcome generalization, and patent/generic competition information.

Suggested Improvement
Limit claims to information actually present in the provided label excerpts (e.g., PD-1 blocking antibody description). Remove approval-year/date, patent expiration, generic-competition speculation, and year-specific trial linkage unless the corresponding label text is provided.

Drug Brand Mention Assessment

Branding Score
61
Visibility
76
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
mentioned only
Brand Perception
Best Known For

Keytruda first received FDA approval on September 4, 2014

Core Claims
  • Keytruda first received FDA approval on September 4, 2014, for unresectable or metastatic melanoma.
  • Keytruda is a checkpoint inhibitor.
  • Keytruda has expanded indications including NSCLC, head and neck cancer, classical Hodgkin lymphoma, and renal cell carcinoma.
  • Keytruda has improved overall survival rates for patients with NSCLC and melanoma.
  • Keytruda's patent is set to expire in 2028, which may lead to generic competition.
Differentiators
  • Described as a checkpoint inhibitor that releases the brakes on the immune system.
  • Presented as first FDA approval for a checkpoint inhibitor.
  • Includes a detailed approval timeline with multiple later indication expansions.
Pricing Perception: Not Mentioned